- Home
- VEL vs RLAY Comparison
VEL vs RLAY Comparison
Compare VEL & RLAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VEL
- RLAY
- Stock Information
- Founded
- VEL 2004
- RLAY 2015
- Country
- VEL United States
- RLAY United States
- Employees
- VEL N/A
- RLAY N/A
- Industry
- VEL Finance: Consumer Services
- RLAY Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- VEL Finance
- RLAY Health Care
- Exchange
- VEL Nasdaq
- RLAY Nasdaq
- Market Cap
- VEL 598.5M
- RLAY 490.3M
- IPO Year
- VEL 2020
- RLAY 2020
- Fundamental
- Price
- VEL $17.11
- RLAY $3.36
- Analyst Decision
- VEL Buy
- RLAY Strong Buy
- Analyst Count
- VEL 4
- RLAY 11
- Target Price
- VEL $21.25
- RLAY $18.40
- AVG Volume (30 Days)
- VEL 157.5K
- RLAY 1.5M
- Earning Date
- VEL 07-31-2025
- RLAY 05-05-2025
- Dividend Yield
- VEL N/A
- RLAY N/A
- EPS Growth
- VEL 14.80
- RLAY N/A
- EPS
- VEL 1.94
- RLAY N/A
- Revenue
- VEL $177,987,000.00
- RLAY $7,679,000.00
- Revenue This Year
- VEL N/A
- RLAY $14.58
- Revenue Next Year
- VEL $32.82
- RLAY N/A
- P/E Ratio
- VEL $8.77
- RLAY N/A
- Revenue Growth
- VEL 39.36
- RLAY N/A
- 52 Week Low
- VEL $16.12
- RLAY $1.78
- 52 Week High
- VEL $20.98
- RLAY $10.72
- Technical
- Relative Strength Index (RSI)
- VEL 55.69
- RLAY 62.06
- Support Level
- VEL $16.60
- RLAY $3.16
- Resistance Level
- VEL $16.95
- RLAY $3.39
- Average True Range (ATR)
- VEL 0.33
- RLAY 0.21
- MACD
- VEL 0.10
- RLAY 0.04
- Stochastic Oscillator
- VEL 100.00
- RLAY 87.77
About VEL Velocity Financial Inc.
Velocity Financial Inc is a United States-based real estate finance company. The company originates and manages investor loans secured by residential rental and small commercial properties. The company earns revenue in the form of interest income. It operates in New York, California, Florida, New Jersey, and other states.
About RLAY Relay Therapeutics Inc.
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. the Dynamo platform integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-4008, RLY-2608, and GDC-1971 (formerly known as RLY-1971).